Evidence map›Paper›PMID 31808398›Full record

ArticleInternational braz j urol : official journal of the Brazilian Society of Urology

Seminal citrate is superior to PSA for detecting clinically significant prostate cancer.

Emerson Pereira Gregorio, Antonio Paulo Alexandrino, Ivania Terezinha Albrecht Schuquel, Willian Ferreira da Costa, Marco Aurelio de Freitas Rodrigues

Open access · diamondAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. 1H NMR-based metabonomics for infertility diagnosis in men with varicocele.Journal of assisted reproduction and genetics · 2020
    Article
  9. Impact of lifestyle in prostate cancer patients. What should we do?International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Emerson Pereira GregorioPontifícia Universidade Católica do Paraná (PUCPR), Faculdade de Medicina, Londrina, PR, Brasil.
Antonio Paulo AlexandrinoDisciplina de Urologia, Departamento de Cirurgia Clínica, Universidade Estadual de Londrina (UEL), Londrina, PR, Brasil.
Ivania Terezinha Albrecht SchuquelDepartamento de Química, Universidade Estadual de Maringá (Universidade Estadual de Maringá-UEM), Maringá, PR, Brasil.
Willian Ferreira da CostaDepartamento de Química, Universidade Estadual de Maringá (Universidade Estadual de Maringá-UEM), Maringá, PR, Brasil.
Marco Aurelio de Freitas RodriguesDisciplina de Urologia, Departamento de Cirurgia Clínica, Universidade Estadual de Londrina (UEL), Londrina, PR, Brasil.
Universidade Estadual de Londrina · BRUniversidade Estadual de Maringá · BRPontifícia Universidade Católica do Paraná · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo establish whether the citrate concentration in the seminal fluid ([CITRATE]) measured by means of high-resolution nuclear magnetic resonance spectroscopy (1HNMRS) is superior to the serum prostate-specific antigen (PSA) concentration in detecting of clinically significant prostate cancer (csPCa) in men with persistently elevated PSA. MATERIALS AND

methodsThe group of patients consisted of 31 consecutively seen men with histological diagnosis of clinically localized csPCa. The control group consisted of 28 men under long-term follow-up (mean of 8.7 ± 3.0 years) for benign prostate hyperplasia (BPH), with persistently elevated PSA (above 4 ng/mL) and several prostate biopsies negative for cancer (mean of 2.7 ± 1.3 biopsies per control). Samples of blood and seminal fluid (by masturbation) for measurement of PSA and citrate concentration, respectively, were collected from patients and controls. Citrate concentration in the seminal fluid ([CITRATE]) was determined by means of 1HNMRS. The capacities of PSA and [CITRATE] to predict csPCa were compared by means of univariate analysis and receiver operating characteristic (ROC) curves.

resultsMedian [CITRATE] was significantly lower among patients with csPCa compared to controls (3.93 mM/l vs. 15.53 mM/l). There was no significant difference in mean PSA between patients and controls (9.42 ng/mL vs. 8.57 ng/mL). The accuracy of [CITRATE] for detecting csPCa was significantly superior compared to PSA (74.8% vs. 54.8%).

conclusionMeasurement of [CITRATE] by means of 1HNMRS is superior to PSA for early detection of csPCa in men with elevated PSA.

Indexed as

AgedBiomarkers, TumorBiopsyCitric AcidHumansMaleMiddle AgedProstate-Specific AntigenProstatic HyperplasiaProstatic NeoplasmsReproducibility of ResultsRisk AssessmentSemenSensitivity and SpecificityStatistics, NonparametricBiomarkers, TumorCitric AcidProstate-Specific AntigenCitratesProstate cancer, familial [Supplementary Concept]Prostate-Specific Antigen

Identifiers

PMID31808398
PMCPMC6909860
OpenAlexW2995087063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.